A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects

To Explore the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Multiple Doses of HRS-7535 in Obese Subjects

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of HRS-7535 tablet in obese subjects.

Study Overview

• Status: Completed
• Conditions: Overweight or Obesity
• Intervention / Treatment: Drug: HRS-7535 Tablet; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 74
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China, 010000
      • Peking University Peoples Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Able and willing to provide a written informed consent.
2. At screening: BMI ≥30 kg/m2.
3. Have been controlled by diet and exercise for 3 months or more before screening, and the change in body weight in the past 3 months is less than 5%.
4. Male and female subjects of childbearing potential through signing the informed consent form to 1 month after the last dose have no family plans and must use highly effective contraception, and female participants of childbearing potential also must have no plans to donate eggs (male participants must have no plans to be sperm donors); Female subjects of childbearing potential must have a serum pregnancy test within 7 days prior to the date of randomization, including the day of randomization.

Exclusion Criteria:

1. Clinically significant abnormalities in relevant laboratory tests at screening.
2. The results of the electrocardiogram at screening show clinically significant abnormalities that may affect the safety of the subject, including but not limited to myocardial infarction, severe arrhythmias such as supraventricular tachycardia, atrial fibrillation, atrial flutter, second- or third-degree atrioventricular block, etc.
3. Heart rate or pulse > 100 beats per minute or ECG QTcF >450 ms at screening.
4. The PHQ-9 score ≥ 15 points.
5. Poor blood pressure control at screening.
6. Presence or history of endocrine disease that may significantly affect body weight at screening.
7. History of diabetes mellitus.
8. Within 6 months prior to screening, the subject has the following diseases of clinical significance: including but not limited to neurological, psychiatric, cardiovascular, endocrine, gastrointestinal, respiratory, urinary, blood, immune system and other diseases, which may interfere with the trial results or pose additional risks to the administration of the study drug as judged by the investigator.
9. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
10. Previous or known history of acute or chronic pancreatitis, history of cholecystitis or history of gallstones, chronic malabsorption syndrome or cholestasis.
11. Severe cardiovascular and cerebrovascular diseases within 6 months prior to screening, including but not limited to: heart failure (NYHA grade II-IV), angina, stroke or transient ischemic attack, myocardial infarction, severe arrhythmia, or coronary artery bypass grafting or percutaneous coronary intervention, etc.; and/or planned revascularization of the coronary arteries, carotid arteries, or peripheral arteries at the time of screening.
12. Any malignant tumor of any organ system within 5 years, regardless of whether there is evidence of local recurrence or metastasis, except for cured local cancer, such as: local basal cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the prostate.
13. Those who have had serious infections, severe trauma, major and medium-sized surgeries, or planned to undergo surgery during the trial within 6 months prior to screening.
14. Those with or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia or other more serious mental illness; or mentally incapacitated or with a language impairment that is unable to fully understand the trial protocol or is unwilling to collaborate with study center staff.
15. Presence of a history of acute or chronic hepatitis or other serious liver disease other than non-alcoholic fatty liver disease.
16. Presence of any blood disorder (e.g., hemolytic anemia, sickle cell disease, etc.) that may interfere with HbA1c detection.
17. Autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis).

18. Use of medications or treatments that may cause significant weight gain or loss within 2 months prior to screening:

    • glucocorticoids (short-term systemic use< 7 days or topical, inhaled, intraocular and nasal administration);
    • tricyclic antidepressants, atypical antipsychotics and mood stabilizers (such as imipramine, chlorpromazine, amitriptyline, mirtazapine, clozapine, olanzapine, paroxetine, phenelzine, thioridazine, valproic acid and its derivatives, lithium salts, etc.);
    • Orlistat, GLP-1 receptor agonists, or incretins, or other weight-loss therapies other than diet and exercise (including GLP-1 receptor agonists, multi-targeted agents);
    • Other medications or treatments that may significantly affect blood sugar or body weight (eg, metformin, SGLT-2 inhibitors, etc.).
19. Undergoing or planning bariatric surgery or weight-loss therapy based on endoscopy and/or medical devices, etc. during the study period (except for a history of liposuction surgery greater than 1 year).
20. Prior discontinuation of GLP-1 receptor agonist-containing agents for safety and/or tolerability reasons.
21. whichever is longer: Participated in a clinical trial of any drug or medical device within 3 months prior to screening or is still within 5 half-lives of the investigational drug. Participation in clinical trials is defined as: signing informed consent and using investigational drugs (including placebo) or investigational medical devices; Participated in clinical trials of drugs containing GLP-1 receptor agonists (including placebo) within 6 months prior to screening.
22. Known or suspected hypersensitivity to GLP-1 receptor agonist drugs, the investigational drug or its components, or its excipients.
23. Addiction to tobacco and alcohol.
24. Those who have a history of blood donation or blood loss of ≥400ml within 3 months before screening or have received blood transfusion within 2 months.
25. Subjects who are mentally incapacitated or have language impairment who cannot fully understand or participate in the trial process.
26. Females who are pregnant, lactating, planning to become pregnant during the trial, or subjects of childbearing potential who are unwilling to use highly effective contraception during the trial period (starting from signing the informed consent form) and within 1 month after the last dose.
27. Inability to tolerate venipuncture blood sampling or needle phobia.
28. Any condition judged by the investigator to be unsuitable to participate in this clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

12

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment group A; HRS-7535 Tablet at dose level 1	Drug: HRS-7535 Tablet; at multiple dose levels
Experimental: Treatment group B; HRS-7535 Tablet at dose level 2	Drug: HRS-7535 Tablet; at multiple dose levels
Experimental: Treatment group C; HRS-7535 Tablet at dose level 3	Drug: HRS-7535 Tablet; at multiple dose levels
Experimental: Treatment group D; HRS-7535 Tablet at dose level 4	Drug: HRS-7535 Tablet; at multiple dose levels
Placebo Comparator: Treatment group E; Placebo at dose level 1	Drug: Placebo; at multiple dose levels (matching active arm HRS-7535 Tablet)
Placebo Comparator: Treatment group F; Placebo at dose level 2	Drug: Placebo; at multiple dose levels (matching active arm HRS-7535 Tablet)
Placebo Comparator: Treatment group G; Placebo at dose level 3	Drug: Placebo; at multiple dose levels (matching active arm HRS-7535 Tablet)
Placebo Comparator: Treatment group H; Placebo at dose level 4	Drug: Placebo; at multiple dose levels (matching active arm HRS-7535 Tablet)
Experimental: Treatment group I; HRS-7535 Tablet at dose level 1 or level 2 or level 3 or level 4.	Drug: HRS-7535 Tablet; at multiple dose levels
Experimental: Treatment group J; HRS-7535 Tablet at dose level 1 or level 2 or level 3 or level 4.	Drug: HRS-7535 Tablet; at multiple dose levels
Placebo Comparator: Treatment group K; Placebo at dose level 1 or level 2.	Drug: Placebo; at multiple dose levels (matching active arm HRS-7535 Tablet)
Placebo Comparator: Treatment group L; Placebo at dose level 1 or level 2.	Drug: Placebo; at multiple dose levels (matching active arm HRS-7535 Tablet)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of Adverse Events	24 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Pharmacokinetic endpoint: Concentration of HRS-7535 in plasma	24 weeks
Change in fasting weight at week 24	24 weeks
Change in waist circumference at week 24	24 weeks

Collaborators and Investigators

• Sponsor: Shandong Suncadia Medicine Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): October 30, 2024
• Primary Completion (Actual): July 14, 2025
• Study Completion (Actual): July 14, 2025

Study Registration Dates

• First Submitted: September 29, 2024
• First Submitted That Met QC Criteria: September 29, 2024
• First Posted (Actual): October 1, 2024

Study Record Updates

• Last Update Posted (Actual): August 24, 2026
• Last Update Submitted That Met QC Criteria: August 20, 2026
• Last Verified: August 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nutrition Disorders; Overnutrition; Body Weight; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Overweight; Obesity
• Other Study ID Numbers: HRS-7535-107

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No